Search results
Results from the WOW.Com Content Network
Biocon Limited is an Indian biopharmaceutical company based in Bengaluru, India.It was founded by Kiran Mazumdar-Shaw in 1978. [4] The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, [5] including the United States and Europe. [4]
In February 2022, Viatris announced an agreement where it will contribute to Biocon Biologics its biosimilars portfolio and related commercial and operational capabilities in exchange for up to $3.335 billion, including a stake of at least 12.9% in Biocon Biologics. [11] The transaction was completed in November 2022. [12]
Kiran Mazumdar-Shaw (born 23 March 1953) is an Indian billionaire entrepreneur. [3] She is the executive chairperson and founder of Biocon Limited and Biocon Biologics Limited, [4] a biotechnology company based in Bangalore, India [5] and the former chairperson of Indian Institute of Management, Bangalore. [6]
Biopharmaceutical company Biocon Ltd reported a more than six-fold rise in first-quarter profit on Thursday, boosted by a one-time gain from the sale of its Indian branded formulations business.
The first Indian biotechnology company to be established was Biocon, which was founded by Kiran Mazumdar-Shaw in 1978. [3] The Indian biotechnology industry formally began in 1986 with the establishment of the Department of Biotechnology (DBT) by the Ministry of Science and Technology. [4]
The launch of the copycat version, branded as Hulio, adds to a list of biosimilars introduced by drugmakers on Monday by Coherus Biosciences and Germany's Fresenius. Boehringer Ingelheim and Swiss ...
From July 2012 to December 2012, if you bought shares in companies when Kevin W. Warsh joined the board, and sold them when he left, you would have a -1.5 percent return on your investment, compared to a 4.9 percent return from the S&P 500.
From August 2012 to December 2012, if you bought shares in companies when Sharon L. Allen joined the board, and sold them when she left, you would have a 60.8 percent return on your investment, compared to a 3.7 percent return from the S&P 500.